Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822
Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution
Mariarosaria D'Amato, Department of Oncology, Ospedale San Rocco ASL Caserta, Sessa Aurunca 81037, Campania, Italy
Gennaro Iengo, Nicola Massa, Chiara Carlomagno, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples 80131, Campania, Italy
Author contributions: D’Amato M and Carlomagno C participated in the conception and design of the study, analyzed the data, and wrote the original manuscript; D’Amato M collected the data; D’Amato M, Iengo G, Massa N, and Carlomagno C critically reviewed and provided final approval of the manuscript; D’Amato M, Iengo G, Massa N, and Carlomagno C were responsible for the decision to submit the manuscript for publication.
Institutional review board statement: The investigation was approved by the panel of scientists proposing the research and by all the collaborators who participated in the research.
Informed consent statement: The need for patient consent was waived due to the retrospective nature of the study.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mariarosaria D'Amato, MD, Doctor, Department of Oncology, Ospedale San Rocco ASL Caserta, Via XXI Luglio, Sessa Aurunca 81037, Campania, Italy.
Received: May 15, 2024
Revised: August 14, 2024
Accepted: August 28, 2024
Published online: January 15, 2025
Processing time: 210 Days and 15.5 Hours
Revised: August 14, 2024
Accepted: August 28, 2024
Published online: January 15, 2025
Processing time: 210 Days and 15.5 Hours
Core Tip
Core Tip: In this retrospective study, we report the prevalence of DPYD polymorphisms in a real-world population of patients treated for gastrointestinal malignancies and their impact on fluoropyrimidine tolerability. Furthermore, we demonstrate that the presence of polymorphisms in the DPYD gene, which encodes dihydropyrimidine dehydrogenase, leads to an increased risk of G3/G4 nonhematologic toxicity and more frequent dose reductions. We did not find a significant difference in chemotherapy delay.